Real world data of efficacy and safety of erlotinib as first-line TKI treatment in EGFR mutation-positive advanced non-small cell lung cancer: Results from the EGFR-2013-CPHG study
Phase III clinical trials have demonstrated the merits of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKI) in the treatment of non-small cell lung cancer (NSCLC) patients with EGFR-activating mutations. Using a cohort of unselected patients treated with erlotinib, we sought t...
Gespeichert in:
| Veröffentlicht in: | Respiratory medicine and research 2021-11, Vol.80, p.100795-100795, Article 100795 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 100795 |
|---|---|
| container_issue | |
| container_start_page | 100795 |
| container_title | Respiratory medicine and research |
| container_volume | 80 |
| creator | Payen, T. Trédaniel, J. Moreau, L. Larivé, S. Le Treut, J. Nocent, C. Hominal, S. Grangeon, V. Bizec, J.-L. Molinier, O. Debieuvre, D. |
| description | Phase III clinical trials have demonstrated the merits of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKI) in the treatment of non-small cell lung cancer (NSCLC) patients with EGFR-activating mutations. Using a cohort of unselected patients treated with erlotinib, we sought to further describe patient and tumour characteristics, and to evaluate their progression-free survival (PFS) and overall survival (OS).
Overall, 44 pulmonologists included patients with the required characteristics as follows: Stage IIIB-IV NSCLC, EGFR-activating mutation, age≥18 years, and having to start erlotinib therapy or receiving erlotinib therapy as the first-line TKI, regardless of treatment-line. The analyses were performed using R software, with survival rates calculated according to the Kaplan–Meier method.
A total of 177 patients, aged 72 years on average, were enrolled over a 2-year period. The cohort included 123 women (69.5%), 158 Caucasians (89.3%), 112 non-smokers (63.2%), and 167 adenocarcinomas (94.3%), at either stage IIIB (21) or IV (156), with a good performance status (PS 0–1, 127). Overall, 40 exhibited brain metastases at baseline (22.6%), while 75 had undergone earlier treatment (42.4%). Median PFS was 11.7 months and OS 25.8 months, with respectively a 1-year rate of 48.6% and 74%. The risk of death correlated with ECOG status (PS=2, HR=4.48, P |
| doi_str_mv | 10.1016/j.resmer.2020.100795 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2550261121</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2590041220300519</els_id><sourcerecordid>2550261121</sourcerecordid><originalsourceid>FETCH-LOGICAL-c362t-637fb8839dc160c01aaea8fd4ef4106e825cb988afa971aa0685c78723b55bca3</originalsourceid><addsrcrecordid>eNp9UctuFDEQHCEQiUL-AKE-cpnF9rw5IKFVsokSCbQKZ6vHboNXM_Ziexbtf_GBzGQTxImLbVVXVXe7suwtZyvOeP1htwoURworwcQCsaarXmTnoupYzkouXv7zPssuY9wxxgRvOGvL19lZUYpSdE1xnv3eEg7wy4dBg8aE4A2QMVahOgI6DRENpeMjHAafrLM9YARjQ0z5YB3Bw90tpECYRnIJrIOrzfUWxilhst7lex9tsgcC1Ad0ijS4GY0jDgMomo9hct9BLaXwEbYUpyHN_sGPkH7Qo1kuGC_y9debDcQ06eOb7JXBIdLl032Rfbu-eljf5PdfNrfrz_e5KmqR8rpoTN-2RacVr5liHJGwNbokU3JWUysq1Xdtiwa7Zi6yuq1U0zai6KuqV1hcZO9Pvvvgf04UkxxtXGZGR36KUlQVEzXngs_U8kRVwccYyMh9sCOGo-RMLpHJnTxFJpfI5CmyWfbuqcPUj6T_ip4DmgmfTgSa9zzYWR6VpeUbbSCVpPb2_x3-AGJyqg0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2550261121</pqid></control><display><type>article</type><title>Real world data of efficacy and safety of erlotinib as first-line TKI treatment in EGFR mutation-positive advanced non-small cell lung cancer: Results from the EGFR-2013-CPHG study</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Payen, T. ; Trédaniel, J. ; Moreau, L. ; Larivé, S. ; Le Treut, J. ; Nocent, C. ; Hominal, S. ; Grangeon, V. ; Bizec, J.-L. ; Molinier, O. ; Debieuvre, D.</creator><creatorcontrib>Payen, T. ; Trédaniel, J. ; Moreau, L. ; Larivé, S. ; Le Treut, J. ; Nocent, C. ; Hominal, S. ; Grangeon, V. ; Bizec, J.-L. ; Molinier, O. ; Debieuvre, D.</creatorcontrib><description>Phase III clinical trials have demonstrated the merits of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKI) in the treatment of non-small cell lung cancer (NSCLC) patients with EGFR-activating mutations. Using a cohort of unselected patients treated with erlotinib, we sought to further describe patient and tumour characteristics, and to evaluate their progression-free survival (PFS) and overall survival (OS).
Overall, 44 pulmonologists included patients with the required characteristics as follows: Stage IIIB-IV NSCLC, EGFR-activating mutation, age≥18 years, and having to start erlotinib therapy or receiving erlotinib therapy as the first-line TKI, regardless of treatment-line. The analyses were performed using R software, with survival rates calculated according to the Kaplan–Meier method.
A total of 177 patients, aged 72 years on average, were enrolled over a 2-year period. The cohort included 123 women (69.5%), 158 Caucasians (89.3%), 112 non-smokers (63.2%), and 167 adenocarcinomas (94.3%), at either stage IIIB (21) or IV (156), with a good performance status (PS 0–1, 127). Overall, 40 exhibited brain metastases at baseline (22.6%), while 75 had undergone earlier treatment (42.4%). Median PFS was 11.7 months and OS 25.8 months, with respectively a 1-year rate of 48.6% and 74%. The risk of death correlated with ECOG status (PS=2, HR=4.48, P<0.001) but not with brain metastasis (HR=1.67, P=0.278).
This study has confirmed erlotinib's efficacy and safety for unselected patients, with PFS and OS comparable to those obtained in phase III trials.</description><identifier>ISSN: 2590-0412</identifier><identifier>EISSN: 2590-0412</identifier><identifier>DOI: 10.1016/j.resmer.2020.100795</identifier><identifier>PMID: 34242973</identifier><language>eng</language><publisher>France: Elsevier Masson SAS</publisher><subject>Adolescent ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - genetics ; Clinical Trials, Phase III as Topic ; EGFR-TKI ; ErbB Receptors - genetics ; Erlotinib ; Erlotinib Hydrochloride - adverse effects ; Female ; Humans ; Lung Neoplasms - drug therapy ; Lung Neoplasms - genetics ; Mutation ; Non-small cell lung cancer ; Overall survival ; Progression-free survival</subject><ispartof>Respiratory medicine and research, 2021-11, Vol.80, p.100795-100795, Article 100795</ispartof><rights>2020 SPLF and Elsevier Masson SAS</rights><rights>Copyright © 2020 SPLF and Elsevier Masson SAS. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c362t-637fb8839dc160c01aaea8fd4ef4106e825cb988afa971aa0685c78723b55bca3</citedby><cites>FETCH-LOGICAL-c362t-637fb8839dc160c01aaea8fd4ef4106e825cb988afa971aa0685c78723b55bca3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27907,27908</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34242973$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Payen, T.</creatorcontrib><creatorcontrib>Trédaniel, J.</creatorcontrib><creatorcontrib>Moreau, L.</creatorcontrib><creatorcontrib>Larivé, S.</creatorcontrib><creatorcontrib>Le Treut, J.</creatorcontrib><creatorcontrib>Nocent, C.</creatorcontrib><creatorcontrib>Hominal, S.</creatorcontrib><creatorcontrib>Grangeon, V.</creatorcontrib><creatorcontrib>Bizec, J.-L.</creatorcontrib><creatorcontrib>Molinier, O.</creatorcontrib><creatorcontrib>Debieuvre, D.</creatorcontrib><title>Real world data of efficacy and safety of erlotinib as first-line TKI treatment in EGFR mutation-positive advanced non-small cell lung cancer: Results from the EGFR-2013-CPHG study</title><title>Respiratory medicine and research</title><addtitle>Respir Med Res</addtitle><description>Phase III clinical trials have demonstrated the merits of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKI) in the treatment of non-small cell lung cancer (NSCLC) patients with EGFR-activating mutations. Using a cohort of unselected patients treated with erlotinib, we sought to further describe patient and tumour characteristics, and to evaluate their progression-free survival (PFS) and overall survival (OS).
Overall, 44 pulmonologists included patients with the required characteristics as follows: Stage IIIB-IV NSCLC, EGFR-activating mutation, age≥18 years, and having to start erlotinib therapy or receiving erlotinib therapy as the first-line TKI, regardless of treatment-line. The analyses were performed using R software, with survival rates calculated according to the Kaplan–Meier method.
A total of 177 patients, aged 72 years on average, were enrolled over a 2-year period. The cohort included 123 women (69.5%), 158 Caucasians (89.3%), 112 non-smokers (63.2%), and 167 adenocarcinomas (94.3%), at either stage IIIB (21) or IV (156), with a good performance status (PS 0–1, 127). Overall, 40 exhibited brain metastases at baseline (22.6%), while 75 had undergone earlier treatment (42.4%). Median PFS was 11.7 months and OS 25.8 months, with respectively a 1-year rate of 48.6% and 74%. The risk of death correlated with ECOG status (PS=2, HR=4.48, P<0.001) but not with brain metastasis (HR=1.67, P=0.278).
This study has confirmed erlotinib's efficacy and safety for unselected patients, with PFS and OS comparable to those obtained in phase III trials.</description><subject>Adolescent</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - genetics</subject><subject>Clinical Trials, Phase III as Topic</subject><subject>EGFR-TKI</subject><subject>ErbB Receptors - genetics</subject><subject>Erlotinib</subject><subject>Erlotinib Hydrochloride - adverse effects</subject><subject>Female</subject><subject>Humans</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - genetics</subject><subject>Mutation</subject><subject>Non-small cell lung cancer</subject><subject>Overall survival</subject><subject>Progression-free survival</subject><issn>2590-0412</issn><issn>2590-0412</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UctuFDEQHCEQiUL-AKE-cpnF9rw5IKFVsokSCbQKZ6vHboNXM_Ziexbtf_GBzGQTxImLbVVXVXe7suwtZyvOeP1htwoURworwcQCsaarXmTnoupYzkouXv7zPssuY9wxxgRvOGvL19lZUYpSdE1xnv3eEg7wy4dBg8aE4A2QMVahOgI6DRENpeMjHAafrLM9YARjQ0z5YB3Bw90tpECYRnIJrIOrzfUWxilhst7lex9tsgcC1Ad0ijS4GY0jDgMomo9hct9BLaXwEbYUpyHN_sGPkH7Qo1kuGC_y9debDcQ06eOb7JXBIdLl032Rfbu-eljf5PdfNrfrz_e5KmqR8rpoTN-2RacVr5liHJGwNbokU3JWUysq1Xdtiwa7Zi6yuq1U0zai6KuqV1hcZO9Pvvvgf04UkxxtXGZGR36KUlQVEzXngs_U8kRVwccYyMh9sCOGo-RMLpHJnTxFJpfI5CmyWfbuqcPUj6T_ip4DmgmfTgSa9zzYWR6VpeUbbSCVpPb2_x3-AGJyqg0</recordid><startdate>202111</startdate><enddate>202111</enddate><creator>Payen, T.</creator><creator>Trédaniel, J.</creator><creator>Moreau, L.</creator><creator>Larivé, S.</creator><creator>Le Treut, J.</creator><creator>Nocent, C.</creator><creator>Hominal, S.</creator><creator>Grangeon, V.</creator><creator>Bizec, J.-L.</creator><creator>Molinier, O.</creator><creator>Debieuvre, D.</creator><general>Elsevier Masson SAS</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202111</creationdate><title>Real world data of efficacy and safety of erlotinib as first-line TKI treatment in EGFR mutation-positive advanced non-small cell lung cancer: Results from the EGFR-2013-CPHG study</title><author>Payen, T. ; Trédaniel, J. ; Moreau, L. ; Larivé, S. ; Le Treut, J. ; Nocent, C. ; Hominal, S. ; Grangeon, V. ; Bizec, J.-L. ; Molinier, O. ; Debieuvre, D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c362t-637fb8839dc160c01aaea8fd4ef4106e825cb988afa971aa0685c78723b55bca3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adolescent</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - genetics</topic><topic>Clinical Trials, Phase III as Topic</topic><topic>EGFR-TKI</topic><topic>ErbB Receptors - genetics</topic><topic>Erlotinib</topic><topic>Erlotinib Hydrochloride - adverse effects</topic><topic>Female</topic><topic>Humans</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - genetics</topic><topic>Mutation</topic><topic>Non-small cell lung cancer</topic><topic>Overall survival</topic><topic>Progression-free survival</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Payen, T.</creatorcontrib><creatorcontrib>Trédaniel, J.</creatorcontrib><creatorcontrib>Moreau, L.</creatorcontrib><creatorcontrib>Larivé, S.</creatorcontrib><creatorcontrib>Le Treut, J.</creatorcontrib><creatorcontrib>Nocent, C.</creatorcontrib><creatorcontrib>Hominal, S.</creatorcontrib><creatorcontrib>Grangeon, V.</creatorcontrib><creatorcontrib>Bizec, J.-L.</creatorcontrib><creatorcontrib>Molinier, O.</creatorcontrib><creatorcontrib>Debieuvre, D.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Respiratory medicine and research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Payen, T.</au><au>Trédaniel, J.</au><au>Moreau, L.</au><au>Larivé, S.</au><au>Le Treut, J.</au><au>Nocent, C.</au><au>Hominal, S.</au><au>Grangeon, V.</au><au>Bizec, J.-L.</au><au>Molinier, O.</au><au>Debieuvre, D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Real world data of efficacy and safety of erlotinib as first-line TKI treatment in EGFR mutation-positive advanced non-small cell lung cancer: Results from the EGFR-2013-CPHG study</atitle><jtitle>Respiratory medicine and research</jtitle><addtitle>Respir Med Res</addtitle><date>2021-11</date><risdate>2021</risdate><volume>80</volume><spage>100795</spage><epage>100795</epage><pages>100795-100795</pages><artnum>100795</artnum><issn>2590-0412</issn><eissn>2590-0412</eissn><abstract>Phase III clinical trials have demonstrated the merits of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKI) in the treatment of non-small cell lung cancer (NSCLC) patients with EGFR-activating mutations. Using a cohort of unselected patients treated with erlotinib, we sought to further describe patient and tumour characteristics, and to evaluate their progression-free survival (PFS) and overall survival (OS).
Overall, 44 pulmonologists included patients with the required characteristics as follows: Stage IIIB-IV NSCLC, EGFR-activating mutation, age≥18 years, and having to start erlotinib therapy or receiving erlotinib therapy as the first-line TKI, regardless of treatment-line. The analyses were performed using R software, with survival rates calculated according to the Kaplan–Meier method.
A total of 177 patients, aged 72 years on average, were enrolled over a 2-year period. The cohort included 123 women (69.5%), 158 Caucasians (89.3%), 112 non-smokers (63.2%), and 167 adenocarcinomas (94.3%), at either stage IIIB (21) or IV (156), with a good performance status (PS 0–1, 127). Overall, 40 exhibited brain metastases at baseline (22.6%), while 75 had undergone earlier treatment (42.4%). Median PFS was 11.7 months and OS 25.8 months, with respectively a 1-year rate of 48.6% and 74%. The risk of death correlated with ECOG status (PS=2, HR=4.48, P<0.001) but not with brain metastasis (HR=1.67, P=0.278).
This study has confirmed erlotinib's efficacy and safety for unselected patients, with PFS and OS comparable to those obtained in phase III trials.</abstract><cop>France</cop><pub>Elsevier Masson SAS</pub><pmid>34242973</pmid><doi>10.1016/j.resmer.2020.100795</doi><tpages>1</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2590-0412 |
| ispartof | Respiratory medicine and research, 2021-11, Vol.80, p.100795-100795, Article 100795 |
| issn | 2590-0412 2590-0412 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2550261121 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Adolescent Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Clinical Trials, Phase III as Topic EGFR-TKI ErbB Receptors - genetics Erlotinib Erlotinib Hydrochloride - adverse effects Female Humans Lung Neoplasms - drug therapy Lung Neoplasms - genetics Mutation Non-small cell lung cancer Overall survival Progression-free survival |
| title | Real world data of efficacy and safety of erlotinib as first-line TKI treatment in EGFR mutation-positive advanced non-small cell lung cancer: Results from the EGFR-2013-CPHG study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T14%3A00%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Real%20world%20data%20of%20efficacy%20and%20safety%20of%20erlotinib%20as%20first-line%20TKI%20treatment%20in%20EGFR%20mutation-positive%20advanced%20non-small%20cell%20lung%20cancer:%20Results%20from%20the%20EGFR-2013-CPHG%20study&rft.jtitle=Respiratory%20medicine%20and%20research&rft.au=Payen,%20T.&rft.date=2021-11&rft.volume=80&rft.spage=100795&rft.epage=100795&rft.pages=100795-100795&rft.artnum=100795&rft.issn=2590-0412&rft.eissn=2590-0412&rft_id=info:doi/10.1016/j.resmer.2020.100795&rft_dat=%3Cproquest_cross%3E2550261121%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2550261121&rft_id=info:pmid/34242973&rft_els_id=S2590041220300519&rfr_iscdi=true |